Published on 05.02.20 in Vol 9, No 2 (2020): February
Preprints (earlier versions) of this paper are available at http://preprints.jmir.org/preprint/16929, first published Nov 06, 2019.
Use of Apps to Promote Childhood Vaccination: Protocol for a Systematic Review
Background: The decline in the uptake of routine childhood vaccinations has resulted in outbreaks of vaccine-preventable diseases. Vaccination apps can be used as a tool to promote immunization through the provision of reminders, dissemination of information, peer support, and feedback.
Objective: The aim of this review is to systematically review the evidence on the use of apps to support childhood vaccination uptake, information storage, and record sharing.
Methods: We will identify relevant papers by searching the following electronic databases: PubMed, Embase by Ovid, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and Education Resources Information Center (ERIC). We will review the reference lists of those studies that we include to identify relevant additional papers not initially identified using our search strategy. In addition to the use of electronic databases, we will search for grey literature on the topic. The search strategy will include only terms relating to or describing the intervention, which is app use. As almost all titles and abstracts are in English, 100% of these will be reviewed, but retrieval will be confined to papers written in the English language. We will record the search outcome on a specifically designed record sheet. Two reviewers will select observational and intervention studies, appraise the quality of the studies, and extract the relevant data. All studies will involve the use of apps relating to child vaccinations. The primary outcome is the uptake of vaccinations. Secondary outcomes are as follows: (1) use of app for sharing of information and providing vaccination reminders and (2) use of app for storage of vaccination information; knowledge and decision making by parents regarding vaccination (ie, risks and benefits of vaccination); costs and cost-effectiveness of vaccination apps; use of the app and measures of usability (eg, usefulness, acceptability, and experiences of different users: parents and health care professionals); use of technical standards for development of the app; and adverse events (eg, data leaks and misinformation). We will exclude studies that do not study an app. We anticipate a limited scope for meta-analysis and will provide a narrative overview of findings and tabular summaries of extracted data.
Results: This project was funded by the Sir David Cooksey Fellowship in Healthcare Translation at the University of Oxford, Oxford, United Kingdom. We will submit the full systematic review for publication in the Journal of Medical Internet Research.
Conclusions: This review will follow, where possible, the Cochrane Collaboration and the Centre for Review and Dissemination methodologies for conducting systematic reviews. We will report our findings based on guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The review results will be used to inform the development of a vaccination app.
International Registered Report Identifier (IRRID): PRR1-10.2196/16929
JMIR Res Protoc 2020;9(2):e16929
Crowdfunding campaign to support this specific research
We help JMIR researchers to raise funds to pursue their research and development aimed at tackling important health and technology challenges. If you would like to show your support for this author, please donate using the button below. The funds raised will directly benefit the corresponding author of this article (minus 8% admin fees). Your donations will help this author to continue publishing open access papers in JMIR journals. Donations of over $100 may also be acknowledged in future publications.
Suggested contribution levels: $20/$50/$100
Description of the Issue
Outbreaks of vaccine-preventable diseases, such as the measles, mumps, rubella, and diphtheria, have risen over the past decade [- ]. While mortality rates of vaccine-preventable diseases are relatively low, certain groups, including children under 5 years of age and people with a compromised immune system, are at greater risk of severe complications [ ]. The decline in the uptake of routine childhood vaccinations has been identified as a cause for outbreaks of vaccine-preventable diseases. Immunization coverage has declined for nine routine childhood vaccinations measured at different child ages in England; vaccination rates fell by 0.2%-1% in 2018-2019 compared to the previous year [ ].
There are numerous interrelated reasons for the decline in childhood vaccinations, including concerns about side effects, fear of autism, objection against many injections, moral or religious grounds, costs, access, and other reasons . A commonly mentioned reason is misinformation and false evidence, for example, claims by the discredited ex-physician Andrew Wakefield who linked the measles, mumps, and rubella (MMR) vaccine to autism in 1998 [ ]. Religious and philosophical reasons have been used by certain groups to decline vaccination of their children [ ]. Particular communities have been consistently difficult to engage, for example, male-dominated societies often resist vaccination against human papillomavirus (HPV) [ , ]. The seriousness and relative rarity of these illnesses has reduced some people’s awareness of the importance of vaccination. Visiting a health clinic for vaccinations might be an inconvenience or may also be forgotten about [ ], particularly as reminders to attend a clinic for vaccinations are not part of routine health care in all countries.
Description of the Intervention
There have been several initiatives to improve the uptake of childhood vaccinations in different settings [, ]. These include a range of informational, behavioral, and environmental initiatives. Health care provider initiatives have focused on patient counseling, maximizing the opportunities of each visit, combination vaccines, and automated electronic patient record reminders. Community-based approaches to increase vaccination rates include increasing outreach and educational programs, using recall and reminder strategies, providing financial incentives, and offering vaccinations at nontraditional sites [ ].
Over the past decade, public and private organizations have developed tools to improve vaccination coverage, including vaccination information websites and apps . These apps help health care providers and patients to access reminders for recommended immunization schedules and related vaccine resources and websites; they also allow for changes in the schedules through app updates.
How the Intervention Might Work
Vaccination apps can be used as a tool to provide reminders, information, peer support, and feedback . A cluster randomized controlled trial showed that an app used by village doctors, which included text messages to caregivers, improved full vaccination coverage in China. Village doctors using the app reported improved efficiency in managing childhood vaccinations [ ]. A quasi-experimental pre-post study using an app to electronically register child births and sending text message reminders to parents about upcoming vaccinations showed improved vaccination coverage in rural hard-to-reach and urban street dweller communities in Bangladesh [ ].
Why It Is Important to Do This Review
A systematic review that assessed interventions to improve immunization coverage in England concluded that current practice is insufficient . Vaccination apps might be used to help improve immunization coverage but, to our knowledge, no recent systematic reviews have assessed the evidence on childhood vaccination apps. A systematic review on the design of a vaccination reminder app identified two publications on mobile apps, but the search was limited and conducted in 2015 [ ]. Furthermore, this review did not assess all important quality indicators, including whether the app was secure, usable, engaging, efficacious, and cost-effective [ ].
Our objective is to systematically review the evidence on childhood vaccination apps by assessing the following:
- The uptake of vaccination.
- Knowledge and decision making by parents: risks and benefits of vaccination.
- Costs and cost-effectiveness.
- Use of the app and measures of usability (eg, usefulness, acceptability, and experiences of different users: parents and health care professionals).
- Use of technical standards for development of the app.
- Adverse events (eg, data leaks and misinformation).
This is the protocol for a systematic review of the literature that will be reported, where possible, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P), as provided in[ ]. Our review will follow, where possible, the Cochrane Collaboration [ ] and the Centre for Review and Dissemination [ ] methodologies for conducting systematic reviews.
Criteria for Considering Studies
Types of Studies
We will include observational studies, such as cross-sectional surveys, cohort studies, qualitative studies (eg, interview studies and focus groups), and intervention studies, such as randomized controlled trials and nonrandomized studies (eg, nonrandomized controlled trials, before-and-after studies, and interrupted-time-series studies). We will only include studies reported in English and published after 2008, when the first smartphone was launched.
Types of Participants
We will include studies involving children up to 18 years of age, the children’s parents or guardians, and health care providers in any country. We will exclude studies focusing on vaccination of adults.
Types of Interventions
We will include any studies assessing apps designed to support childhood vaccination uptake, information storage, and record sharing (see). We will exclude studies that do not involve the use or study of an app for childhood vaccinations and that solely focus on other ways of delivering vaccination interventions, such as text messaging, telephone calls, or a website [ , ].
|Child’s age||Where vaccination is given||Vaccine|
|Birth||Hospital or clinic||Bacille Calmette-Guerin (BCG) vaccine: a vaccine to protect against tuberculosis disease|
|2 months||General practitioner||6 in 1: vaccines against diphtheria, tetanus, whooping cough (ie, pertussis), polio, Haemophilus influenzae type b (Hib), and hepatitis B provided in one single injection|
Vaccines against pneumococcal disease, meningococcal B, and rotavirus disease
|4 months||General practitioner||6 in 1: vaccines against diphtheria, tetanus, whooping cough (ie, pertussis), polio, Haemophilus influenzae type b (Hib), and hepatitis B provided in one single injection|
Vaccines against meningococcal B and rotavirus disease
|6 months||General practitioner||6 in 1: vaccines against diphtheria, tetanus, whooping cough (ie, pertussis), polio, Haemophilus influenzae type b (Hib), and hepatitis B provided in one single injection|
Vaccines against pneumococcal disease and meningococcal C
|12 months||General practitioner||Measles, mumps, and rubella (MMR) vaccine|
Vaccine against meningococcal B
|13 months||General practitioner||Vaccines against meningococcal C, Haemophilus influenzae type b (Hib), and pneumococcal disease|
|4-5 years||General practitioner or school||4 in 1: vaccines against diphtheria, tetanus, whooping cough (ie, pertussis), and polio|
Measles, mumps, and rubella (MMR) vaccine
|11-14 years||School||Tetanus and low-dose diphtheria and pertussis (Tdap) booster|
Meningococcal C booster
Human papillomavirus (HPV) vaccine (2 doses)
Types of Comparators
We will include any type of comparator interventions.
Types of Outcome Measures
The primary outcome of this review is the uptake of vaccination. Secondary outcomes are knowledge and decision making by parents (ie, risks and benefits of vaccination); costs and cost-effectiveness; use of the app and measures of usability (eg, usefulness, acceptability, and experiences of different users: parents and health care professionals); use of technical standards for development of the app; and adverse events (eg, data leaks and misinformation).
Relevant articles will be identified by searching the following electronic databases: (1) PubMed, (2), Embase through Ovid, (3) Web of Science, (4) Cochrane Central Register of Controlled Trials (CENTRAL) , (5) ClinicalTrials.gov, and (6) Education Resources Information Center (ERIC).
A draft search strategy can be found in. This will be tailored to the different databases, with the assistance of a medical research librarian. No study design filter will be used, as both quantitative and qualitative studies are to be included. We will use the titles, abstracts, and keywords of a set of articles that we know meet our inclusion criteria to define a search strategy that will return all these articles without an unmanageably large number of irrelevant articles.
Data Management, Collection, and Analysis
Selection of Studies
Studies that meet the inclusion criteria will be included in the review. Two reviewers will screen titles and abstracts against the inclusion and exclusion criteria. Where duplicates or publications from the same study are identified, articles will be screened and the more recent publication or the one with the most detail will be selected for inclusion in the review. Two reviewers will assess full texts for eligibility; any disagreement will be resolved through discussion with a third reviewer. Study selection will be demonstrated using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart.
We will pilot the data extraction form on a small number of studies to develop the final data extraction form. One reviewer will extract data from the included studies, which will be validated by a second reviewer. The data extraction form will be based on the minimum requirements as recommended by the Cochrane Handbook for Systematic Reviews of Interventions . The data extraction form will be comprised of a Microsoft Excel form and will include the following about the studies: general information (eg, title, authors, and date); characteristics (eg, study design, aim, duration, and inclusion and exclusion criteria); risk of bias, depending on study design; samples (eg, description, geographic location, and setting); interventions; outcomes, as specified above; and results (eg, outcomes and times of assessment).
Assessment of Methodological Quality and Risk of Bias
Quality assessment will be undertaken by two reviewers. Any disagreements will be resolved by consensus and by including the opinion of a third reviewer. The methods specified in the Cochrane Collaboration’s tool for assessing risk of bias will be used. Three bias assessment categories will be used: low, high, and unclear risk, as specified in the Cochrane Handbook for Systematic Reviews of Interventions ; as specified in this handbook [ ], an adapted version of these domains will also be used for nonrandomized studies. For other types of studies, we will use adapted versions of the following: Cochrane’s Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I) tool [ ], the Critical Appraisal Skills Programme (CASP) tool for qualitative studies [ ], and the Appraisal tool for Cross-Sectional Studies (AXIS) [ ].
Assessment of Heterogeneity
We anticipate a limited scope for meta-analysis due to differences in study populations, interventions, and outcomes. If a sufficient number of studies are found, we will explore heterogeneity through consideration of the study populations, methods, and interventions by visual inspection of results. Also, in statistical terms, we will assess the chi-square test for homogeneity and the I2 statistic. We will define statistically significant heterogeneity as P<.10. The I2 will be assessed with the following levels of inconsistency: I2 of 0%-25% represents a low level of inconsistency; I2 of 26%-50% represents a moderate level of inconsistency; and I2>50% represents a high level of inconsistency.
If a meta-analysis is not possible, we will provide a narrative overview of the findings and tabular summaries of extracted data. If a meta-analysis can be performed, this will allow us to estimate a summary measure of effect on relevant outcomes. For dichotomous outcomes, odds ratios will be used as the summary statistic. For continuous outcomes, mean difference will be the summary statistic. Standard pairwise meta-analysis will be conducted when more than one randomized controlled trial is identified.
If appropriate, we will provide a narrative overview of subgroups, including different interventions, participants, and geographic regions.
This project was funded by the Sir David Cooksey Fellowship in Healthcare Translation at the University of Oxford, Oxford, United Kingdom. We will submit the full systematic review for publication in the Journal of Medical Internet Research.
We will systematically review the evidence on apps to facilitate the vaccination process. Our review will follow, where possible, the Cochrane Collaboration and the Centre for Review and Dissemination methodologies for conducting systematic reviews. We will report our findings based on guidelines from the PRISMA statement. A comprehensive search of the evidence will be conducted. A potential limitation of this review is that the quality and quantity of studies using similar methods and interventions may be limited. The review results will be used to inform the development of a vaccination app.
This work was funded by the Sir David Cooksey Fellowship in Healthcare Translation at the University of Oxford, Oxford, United Kingdom.
MM and EM conceived the study topic. EM and CdC set initial search parameters. MHVV drafted the protocol. EM, MMI, CdC, and MM revised and edited the drafted manuscript.
Conflicts of Interest
Reporting checklist based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines and draft searches.DOCX File , 21 KB
- Hopkins Tanne J. Measles: Two US outbreaks are blamed on low vaccination rates. BMJ 2019 Jan 21;364:l312. [CrossRef] [Medline]
- Greenlee C, Newton S. A review of traditional vaccine-preventable diseases and the potential impact on the otolaryngologist. Int Arch Otorhinolaryngol 2018 Jul 25;22(3):317-329 [FREE Full text] [CrossRef] [Medline]
- Ventola CL. Immunization in the United States: Recommendations, barriers, and measures to improve compliance: Part 1: Childhood vaccinations. P T 2016 Jul;41(7):426-436 [FREE Full text] [Medline]
- Public Health England (PHE). NHS Digital. 2019 Sep 26. Childhood vaccination coverage statistics - England 2018-19. URL: https://digital.nhs.uk/data-and-information/publications/statistical/nhs-immunisation-statistics/england-2018-19 [accessed 2019-12-30]
- Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. Lancet 1999 Jun 12;353(9169):2026-2029. [CrossRef] [Medline]
- Pelčić G, Karačić S, Mikirtichan GL, Kubar OI, Leavitt FJ, Cheng-Tek Tai M, et al. Religious exception for vaccination or religious excuses for avoiding vaccination. Croat Med J 2016 Oct 31;57(5):516-521 [FREE Full text] [CrossRef] [Medline]
- Graham JE, Mishra A. Global challenges of implementing human papillomavirus vaccines. Int J Equity Health 2011 Jun 30;10:27 [FREE Full text] [CrossRef] [Medline]
- Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vaccine 2014 Apr 17;32(19):2150-2159. [CrossRef] [Medline]
- Nelson K, Wallace A, Sodha SV, Daniels D, Dietz V. Assessing strategies for increasing urban routine immunization coverage of childhood vaccines in low and middle-income countries: A systematic review of peer-reviewed literature. Vaccine 2016 Nov 04;34(46):5495-5503 [FREE Full text] [CrossRef] [Medline]
- Walling EB, Benzoni N, Dornfeld J, Bhandari R, Sisk BA, Garbutt J, et al. Interventions to improve HPV vaccine uptake: A systematic review. Pediatrics 2016 Jul;138(1):e20153863 [FREE Full text] [CrossRef] [Medline]
- Immunization Action Coalition. Immunization apps for healthcare providers and their patients. URL: https://www.immunize.org/resources/apps.asp [accessed 2019-12-30]
- Abahussin A, Albarrak A. Vaccination adherence: Review and proposed model. J Infect Public Health 2016;9(6):781-789 [FREE Full text] [CrossRef] [Medline]
- Chen L, Du X, Zhang L, van Velthoven MH, Wu Q, Yang R, et al. Effectiveness of a smartphone app on improving immunization of children in rural Sichuan Province, China: A cluster randomized controlled trial. BMC Public Health 2016 Aug 31;16:909 [FREE Full text] [CrossRef] [Medline]
- Uddin MJ, Shamsuzzaman M, Horng L, Labrique A, Vasudevan L, Zeller K, et al. Use of mobile phones for improving vaccination coverage among children living in rural hard-to-reach areas and urban streets of Bangladesh. Vaccine 2016 Jan 04;34(2):276-283 [FREE Full text] [CrossRef] [Medline]
- Crocker-Buque T, Mounier-Jack S. Vaccination in England: A review of why business as usual is not enough to maintain coverage. BMC Public Health 2018 Dec 06;18(1):1351 [FREE Full text] [CrossRef] [Medline]
- van Velthoven MH, Wyatt J, Meinert E, Brindley D, Wells G. How standards and user involvement can improve app quality: A lifecycle approach. Int J Med Inform 2018 Oct;118:54-57. [CrossRef] [Medline]
- Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015 Jan 02;350:g7647 [FREE Full text] [CrossRef] [Medline]
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. London, UK: The Cochrane Collaboration; 2011 Mar. URL: http://handbook-5-1.cochrane.org/ [accessed 2019-12-30]
- University of York. Centre for Reviews and Dissemination. URL: http://www.york.ac.uk/inst/crd/index_ guidance.htm [accessed 2019-12-30]
- Domek GJ, Contreras-Roldan IL, Bull S, O'Leary ST, Bolaños Ventura GA, Bronsert M, et al. Text message reminders to improve infant immunization in Guatemala: A randomized clinical trial. Vaccine 2019 Sep 30;37(42):6192-6200. [CrossRef] [Medline]
- Shourie S, Jackson C, Cheater FM, Bekker HL, Edlin R, Tubeuf S, et al. A cluster randomised controlled trial of a Web-based decision aid to support parents' decisions about their child's measles mumps and rubella (MMR) vaccination. Vaccine 2013 Dec 05;31(50):6003-6010 [FREE Full text] [CrossRef] [Medline]
- Cochrane Library. Cochrane Central Register of Controlled Trials (CENTRAL). URL: http://www.cochranelibrary.com/about/central-landing-page.html [accessed 2019-12-13]
- Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016 Oct 12;355:i4919 [FREE Full text] [CrossRef] [Medline]
- Critical Appraisal Skills Programme (CASP). CASP Checklist: 10 questions to help you make sense of a qualitative research. URL: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf [accessed 2019-12-30]
- Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open 2016 Dec 08;6(12):e011458 [FREE Full text] [CrossRef] [Medline]
|AXIS: Appraisal tool for Cross-Sectional Studies|
|CASP: Critical Appraisal Skills Programme|
|CENTRAL: Cochrane Central Register of Controlled Trials|
|ERIC: Education Resources Information Center|
|HPV: human papillomavirus|
|JMIR: Journal of Medical Internet Research|
|MMR: measles, mumps, and rubella|
|PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses|
|PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols|
|ROBINS-I: Risk Of Bias In Non-randomized Studies-of Interventions|
Edited by G Eysenbach; submitted 06.11.19; peer-reviewed by N Jarour; accepted 28.11.19; published 05.02.20
©Michelle Helena Van Velthoven, Madison Milne-Ives, Caroline de Cock, Mary Mooney, Edward Meinert. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 05.02.2020.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.